Opinion|Videos|December 2, 2024
Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management
Author(s)Michael Levy, MD, PhD
A panelist discusses how comparing hospitalization rates, relapse risks, and safety considerations between rituximab and other NMOSD therapies, such as complement inhibitors, can provide valuable insights to guide treatment decisions, manage healthcare costs, and optimize patient quality of life.
Advertisement
Video content above is prompted by the following:
- How do hospitalization rates for rituximab compare with those seen in patients treated with complement inhibitors or other therapies?
- What implications will this have on treatment decisions?
- Please review any underlying biological or mechanistic associated with higher relapse rates reported with rituximab.
- What are some key safety considerations beyond relapse rates that may need to be addressed with long-term rituximab use in patients with NMOSD?
- What implications do relapse rates and hospitalization trends have on healthcare costs and patient quality of life in NMOSD management?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
3
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
4
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
5